Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).

Bo ZhangHua ZhongChunlei ShiZhiqiang GaoRunbo ZhongAiqin GuWeimin WangTianqing ChuLiwen XiongWei ZhangHuimin WangXueyan ZhangBao-Hui Han

Published in: The clinical respiratory journal (2023)

We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES-SCLC patients.

Keyphrases

phase ii study
open label
double blind
end stage renal disease
placebo controlled
ejection fraction
chronic kidney disease
newly diagnosed
clinical trial
randomized controlled trial
single cell
stem cells
squamous cell carcinoma
phase iii
bone marrow
mesenchymal stem cells